7XSW
Structure of SARS-CoV-2 antibody S309 with GX/P2V/2017 RBD
7XSW の概要
エントリーDOI | 10.2210/pdb7xsw/pdb |
分子名称 | S309 Heavy Chain, S309 Lambda Chain, Spike protein S1, ... (4 entities in total) |
機能のキーワード | sars-cov-2, gx/p2v/2017, rbd, antibody, s309, fab, viral protein, viral protein-immune system complex, viral protein/immune system |
由来する生物種 | Homo sapiens (human) 詳細 |
タンパク質・核酸の鎖数 | 6 |
化学式量合計 | 146401.56 |
構造登録者 | |
主引用文献 | Jia, Y.,Niu, S.,Hu, Y.,Chai, Y.,Zheng, A.,Su, C.,Wu, L.,Han, P.,Han, P.,Lu, D.,Liu, Z.,Yan, X.,Tian, D.,Chen, Z.,Qi, J.,Tian, W.X.,Wang, Q.,Gao, G.F. Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017. Cell Rep, 41:111831-111831, 2022 Cited by PubMed Abstract: Since the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, multiple SARS-CoV-2-related viruses have been characterized, including pangolin-origin GD/1/2019 and GX/P2V/2017. Our previous study indicated that both viruses have the potential to infect humans. Here, we find that CB6 (commercial name etesevimab), a COVID-19 therapeutic monoclonal antibody (MAb) developed by our group, efficiently inhibits GD/1/2019 but not GX/P2V/2017. A total of 50 SARS-CoV-2 MAbs divided into seven groups based on their receptor-binding domain (RBD) epitopes, together with the COVID-19 convalescent sera, are systematically screened for their cross-binding and cross-neutralizing properties against GX/P2V/2017. We find that GX/P2V/2017 displays substantial immune difference from SARS-CoV-2. Furthermore, we solve two complex structures of the GX/P2V/2017 RBD with MAbs belonging to RBD-1 and RBD-5, providing a structural basis for their different antigenicity. These results highlight the necessity for broad anti-coronavirus countermeasures and shed light on potential therapeutic targets. PubMed: 36493785DOI: 10.1016/j.celrep.2022.111831 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (3.3 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード